Crigler–Najjar syndrome: therapeutic options and consequences of mutations in the UGT1A1 complex

References

• Crigler JF Jr, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics10(2), 169–180 (1952).
   PubMed Web of Science ®Google Scholar
• Gilbert A, Lereboulet P. La cholemie simple familiale. Sem. Med.21, 241–243 (1901).
   Google Scholar
• van der Veere CN, Sinaasappel M, McDonagh AF et al. Current therapy for Crigler–Najjar syndrome type 1: report of a world registry. Hepatology24(2), 311–315 (1996).
   PubMed Web of Science ®Google Scholar
• Sinaasappel M, Jansen PL. The differential diagnosis of Crigler–Najjar disease, types 1 and 2, by bile pigment analysis. Gastroenterology100(3), 783–789 (1991).
   PubMed Web of Science ®Google Scholar
• Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am. J. Med.47(3), 395–409 (1969).
   PubMed Web of Science ®Google Scholar
• Seppen J, Bosma PJ, Goldhoorn BG et al. Discrimination between Crigler–Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J. Clin. Invest.94(6), 2385–2391 (1994).
   PubMed Web of Science ®Google Scholar
• Bosma PJ. Inherited disorders of bilirubin metabolism. J. Hepatol.38(1), 107–117 (2003).
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med.333(18), 1171–1175 (1995).
   PubMed Web of Science ®Google Scholar
• Clementi M, Di Gianantonio E, Fabris L et al. Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene. Dig. Liver Dis.39(4), 351–355 (2007).
   PubMedGoogle Scholar
• Owens D, Evans J. Population studies on Gilbert’s syndrome. J. Med. Genet.12(2), 152–156 (1975).
   PubMed Web of Science ®Google Scholar
• Sieg A, Arab L, Schlierf G, Stiehl A, Kommerell B. Prevalence of Gilbert’s syndrome in Germany. Dtsch Med. Wochenschr.112(31–32), 1206–1208 (1987).
   PubMed Web of Science ®Google Scholar
• Arias IM, London IM. Bilirubin glucuronide formation in vitro; demonstration of a defect in Gilbert’s disease. Science126(3273), 563–564 (1957).
   PubMed Web of Science ®Google Scholar
• Muraca M, Fevery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenterology87(2), 308–313 (1984).
   PubMed Web of Science ®Google Scholar
• Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N. Engl. J. Med.344(8), 581–590 (2001).
   PubMed Web of Science ®Google Scholar
• Ostrow JD, Pascolo L, Shapiro SM, Tiribelli C. New concepts in bilirubin encephalopathy. Eur. J. Clin. Invest.33(11), 988–997 (2003).
   PubMed Web of Science ®Google Scholar
• Martich-Kriss V, Kollias SS, Ball WS Jr. MR findings in kernicterus. Am. J. Neuroradiol.16(4 Suppl.), 819–821 (1995).
   PubMedGoogle Scholar
• Steinborn M, Seelos KC, Heuck A, von Voss H, Reiser M. MR findings in a patient with Kernicterus. Eur. Radiol.9(9), 1913–1915 (1999).
   PubMedGoogle Scholar
• Sugama S, Soeda A, Eto Y. Magnetic resonance imaging in three children with kernicterus. Pediatr. Neurol.25(4), 328–331 (2001).
   PubMedGoogle Scholar
• Hansen TW. Kernicterus in term and near-term infants – the specter walks again. Acta Paediatr.89(10), 1155–1157 (2000).
   PubMed Web of Science ®Google Scholar
• Labrune PH, Myara A, Francoual J, Trivin F, Odievre M. Cerebellar symptoms as the presenting manifestations of bilirubin encephalopathy in children with Crigler–Najjar type I disease. Pediatrics89(4 Pt. 2), 768–770 (1992).
   PubMedGoogle Scholar
• Tabarki B, Khalifa M, Yacoub M, Tlili K, Essoussi AS. Cerebellar symptoms heralding bilirubin encephalopathy in Crigler–Najjar syndrome. Pediatr. Neurol.27(3), 234–236 (2002).
   PubMedGoogle Scholar
• Perretti A, Crispino G, Marcantonio L et al. Clinical utility of electrophysiological evaluation in Crigler–Najjar syndrome. Neuropediatrics38(4), 173–178 (2007).
   PubMedGoogle Scholar
• Sampietro M, Iolascon A. Molecular pathology of Crigler–Najjar type I and II and Gilbert’s syndromes. Haematologica84(2), 150–157 (1999).
   PubMed Web of Science ®Google Scholar
• Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler–Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat.16(4), 297–306 (2000).
   PubMed Web of Science ®Google Scholar
• Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N. Engl. J. Med.358(9), 920–928 (2008).
   PubMed Web of Science ®Google Scholar
• Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J. Biol. Chem.266(2), 1043–1047 (1991).
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Seppen J, Goldhoorn B et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem.269(27), 17960–17964 (1994).
   PubMed Web of Science ®Google Scholar
• Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem.267(5), 3257–3261 (1992).
   PubMed Web of Science ®Google Scholar
• van Es HH, Bout A, Liu J et al. Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37. Cytogenet. Cell. Genet.63(2), 114–116 (1993).
   PubMedGoogle Scholar
• Gong QH, Cho JW, Huang T et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics11(4), 357–368 (2001).
   PubMedGoogle Scholar
• Bosma PJ, Chowdhury NR, Goldhoorn BG et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler–Najjar syndrome, Type I. Hepatology15(5), 941–947 (1992).
   PubMed Web of Science ®Google Scholar
• Aono S, Yamada Y, Keino H et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler–Najjar syndrome type II. Biochem. Biophys. Res. Comm.197(3), 1239–1244 (1993).
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Goldhoorn B, Oude Elferink RP, Sinaasappel M, Oostra BA, Jansen PL. A mutation in bilirubin uridine 5´-diphosphate-glucuronosyltransferase isoform 1 causing Crigler–Najjar syndrome type II. Gastroenterology105(1), 216–220 (1993).
   PubMed Web of Science ®Google Scholar
• Petit F, Gajdos V, Capel L et al. Crigler–Najjar type II syndrome may result from several types and combinations of mutations in the UGT1A1 gene. Clin. Genet.69(6), 525–527 (2006).
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Owens IS, Burchell B et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics7(4), 255–269 (1997).
   PubMedGoogle Scholar
• Monaghan G, Foster B, Jurima-Romet M, Hume R, Burchell B. UGT1*1 genotyping in a Canadian Inuit population. Pharmacogenetics7(2), 153–156 (1997).
   PubMedGoogle Scholar
• Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet347(9001), 578–581 (1996).
   PubMed Web of Science ®Google Scholar
• Kaplan M, Hammerman C, Rubaltelli FF et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology35(4), 905–911 (2002).
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA95(14), 8170–8174 (1998).
   PubMed Web of Science ®Google Scholar
• Ando Y, Chida M, Nakayama K, Saka H, Kamataki T. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics8(4), 357–360 (1998).
   PubMedGoogle Scholar
• Akaba K, Kimura T, Sasaki A et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int.46(1), 21–26 (1998).
   PubMedGoogle Scholar
• Takeuchi K, Kobayashi Y, Tamaki S et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler–Najjar syndrome or Gilbert’s syndrome as well as in healthy Japanese subjects. J. Gastroenterol. Heptatol.19(9), 1023–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Pett S, Mowat AP. Crigler–Najjar syndrome types I and II. Clinical experience – King’s College Hospital 1972–1978. Phenobarbitone, phototherapy and liver transplantation. Mol. Aspects Med.9(5), 473–482 (1987).
   PubMedGoogle Scholar
• Suresh G, Lucey JF. Lack of deafness in Crigler–Najjar syndrome type 1: a patient survey. Pediatrics100(5), E9 (1997).
   Web of Science ®Google Scholar
• Ahmed P, Pratt A, Land VJ, Flye MW, Chaplin H. Multiple plasma exchanges successfully maintain a young adult patient with Crigler–Najjar syndrome type I. J. Clin. Apher.5(1), 17–20 (1989).
   PubMedGoogle Scholar
• Land VJ, Zarkowsky HS, Vietti TJ. Phototherapy for jaundice. N. Engl. J. Med.282(7), 397 (1970).
   PubMedGoogle Scholar
• Ostrow JD. Therapeutic amelioration of jaundice: old and new strategies. Hepatology8(3), 683–689 (1988).
   PubMedGoogle Scholar
• Cohen AN, Kapitulnik J, Ostrow JD et al. Effects of phenobarbital on bilirubin metabolism and its response to phototherapy in the jaundiced Gunn rat. Hepatology5(2), 310–316 (1985).
   PubMed Web of Science ®Google Scholar
• Caglayan S, Candemir H, Aksit S, Kansoy S, Asik S, Yaprak I. Superiority of oral agar and phototherapy combination in the treatment of neonatal hyperbilirubinemia. Pediatrics92(1), 86–89 (1993).
   PubMed Web of Science ®Google Scholar
• Ulstrom RA, Eisenklam E. The enterohepatic shunting of bilirubin in the newborn infant. I. Use of oral activated charcoal to reduce normal serum bilirubin values. J. Pediatr.65, 27–37 (1964).
   PubMed Web of Science ®Google Scholar
• Arrowsmith WA, Payne RB, Littlewood JM. Comparison of treatments for congenital nonobstructive nonhaemolytic hyperbilirubinemia. Arch. Dis. Child.50(3), 197–201 (1975).
   PubMedGoogle Scholar
• van der Veere CN, Schoemaker B, van der Meer R et al. Rapid association of unconjugated bilirubin with amorphous calcium phosphate. J. Lipid Res.36(8), 1697–1707 (1995).
   PubMedGoogle Scholar
• Van Der Veere CN, Schoemaker B, Bakker C, Van Der Meer R, Jansen PL, Elferink RP. Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia. Hepatology24(3), 620–626 (1996).
   PubMedGoogle Scholar
• Van der Veere CN, Jansen PL, Sinaasappel M et al. Oral calcium phosphate: a new therapy for Crigler–Najjar disease? Gastroenterology112(2), 455–462 (1997).
   PubMedGoogle Scholar
• Hafkamp AM, Havinga R, Ostrow JD et al. Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats. Pediatr. Res.59(4 Pt 1), 506–512 (2006).
   PubMed Web of Science ®Google Scholar
• Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ. Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology41(3), 526–534 (2005).
   PubMedGoogle Scholar
• Hafkamp AM, Nelisse-Haak R, Sinaasappel M, Oude Elferink RP, Verkade HJ. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler–Najjar disease: a randomized controlled trial. Pediatr. Res.62(6), 725–730 (2007).
   PubMed Web of Science ®Google Scholar
• Rubaltelli FF, Guerrini P, Reddi E, Jori G. Tin-protoporphyrin in the management of children with Crigler–Najjar disease. Pediatrics84(4), 728–731 (1989).
   PubMedGoogle Scholar
• Otte JB, de Hemptine B, Moulin D et al. Liver transplantation in children. Chir. Pediatr.26(5), 261–273 (1985).
   PubMedGoogle Scholar
• Kayler LK, Rasmussen CS, Dykstra DM et al. Liver transplantation in children with metabolic disorders in the United States. Am. J. Transplant.3(3), 334–339 (2003).
   PubMed Web of Science ®Google Scholar
• Kokudo N, Otsu I, Okazaki T et al. Long-term effects of intrasplenically transplanted adult hepatocytes and fetal liver in hyperbilirubinemic Gunn rats. Transpl. Int.8(4), 262–267 (1995).
   PubMedGoogle Scholar
• Whitington PF, Emond JC, Heffron T, Thistlethwaite JR. Orthotopic auxiliary liver transplantation for Crigler–Najjar syndrome type 1. Lancet342(8874), 779–780 (1993).
   PubMedGoogle Scholar
• Rela M, Muiesan P, Vilca-Melendez H et al. Auxiliary partial orthotopic liver transplantation for Crigler–Najjar syndrome type I. Ann. Surg.229(4), 565–569 (1999).
   PubMedGoogle Scholar
• Schauer R, Stangl M, Lang T et al. Treatment of Crigler–Najjar type 1 disease: relevance of early liver transplantation. J. Pediatr. Surg.38(8), 1227–1231 (2003).
   PubMedGoogle Scholar
• Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation82(4), 441–449 (2006).
   PubMed Web of Science ®Google Scholar
• Matas AJ, Sutherland DE, Steffes MW et al. Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science192(4242), 892–894 (1976).
   PubMed Web of Science ®Google Scholar
• Asonuma K, Gilbert JC, Stein JE, Takeda T, Vacanti JP. Quantitation of transplanted hepatic mass necessary to cure the Gunn rat model of hyperbilirubinemia. J. Pediatr. Surg.27(3), 298–301 (1992).
   PubMed Web of Science ®Google Scholar
• Darwish AA, Sokal E, Stephenne X, Najimi M, de Goyet Jde V, Reding R. Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl.10(9), 1213–1215 (2004).
   PubMed Web of Science ®Google Scholar
• Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J. Inherit. Metab. Dis.29(2–3), 431–435 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm.2, 8 (2005).
   Google Scholar
• Theise ND, Saxena R, Portmann BC et al. The canals of Hering and hepatic stem cells in humans. Hepatology30(6), 1425–1433 (1999).
   PubMed Web of Science ®Google Scholar
• Schmelzer E, Zhang L, Bruce A et al. Human hepatic stem cells from fetal and postnatal donors. J. Exp. Med.204(8), 1973–1987 (2007).
   PubMed Web of Science ®Google Scholar
• Rambhatla L, Chiu CP, Kundu P, Peng Y, Carpenter MK. Generation of hepatocyte-like cells from human embryonic stem cells. Cell. Transplant.12(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Petersen BE, Bowen WC, Patrene KD et al. Bone marrow as a potential source of hepatic oval cells. Science284(5417), 1168–1170 (1999).
   PubMed Web of Science ®Google Scholar
• Theise ND, Krause DS. Bone marrow to liver: the blood of Prometheus. Sem. Cell Dev. Biol.13(6), 411–417 (2002).
   PubMed Web of Science ®Google Scholar
• Alison MR, Poulsom R, Jeffery R et al. Hepatocytes from non-hepatic adult stem cells. Nature406(6793), 257 (2000).
   PubMed Web of Science ®Google Scholar
• Lagasse E, Connors H, Al-Dhalimy M et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med.6(11), 1229–1234 (2000).
   PubMed Web of Science ®Google Scholar
• Sensken S, Waclawczyk S, Knaupp AS et al.In vitro differentiation of human cord blood-derived unrestricted somatic stem cells towards an endodermal pathway. Cytotherapy9(4), 362–378 (2007).
   PubMed Web of Science ®Google Scholar
• Kogler G, Sensken S, Airey JA et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med.200(2), 123–135 (2004).
   PubMed Web of Science ®Google Scholar
• Muraca M, Ferraresso C, Vilei MT et al. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. Gut56(12), 1725–1735 (2007).
   PubMedGoogle Scholar
• Nguyen TH, Bellodi-Privato M, Aubert D et al. Therapeutic lentivirus-mediated neonatal in vivo gene therapy in hyperbilirubinemic Gunn rats. Mol. Ther.12(5), 852–859 (2005).
   PubMedGoogle Scholar
• Takahashi M, Ilan Y, Chowdhury NR, Guida J, Horwitz M, Chowdhury JR. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J. Biol. Chem.271(43), 26536–26542 (1996).
   PubMed Web of Science ®Google Scholar
• Ilan Y, Droguett G, Chowdhury NR et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl Acad. Sci. USA94(6), 2587–2592 (1997).
   PubMed Web of Science ®Google Scholar
• Thummala NR, Ghosh SS, Lee SW et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler–Najjar syndrome. Gene Ther.9(15), 981–990 (2002).
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science302(5644), 415–419 (2003).
   PubMed Web of Science ®Google Scholar
• Toietta G, Mane VP, Norona WS et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc. Natl Acad. Sci. USA102(11), 3930–3935 (2005).
   PubMed Web of Science ®Google Scholar
• Davidoff AM, Gray JT, Ng CY et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with seroType 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther.11(6), 875–888 (2005).
   PubMed Web of Science ®Google Scholar
• Seppen J, Bakker C, de Jong B et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol. Ther.13(6), 1085–1092 (2006).
   PubMed Web of Science ®Google Scholar
• Bellodi-Privato M, Aubert D, Pichard V, Myara A, Trivin F, Ferry N. Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors. Hepatology42(2), 431–438 (2005).
   PubMedGoogle Scholar
• Nguyen TH, Aubert D, Bellodi-Privato M et al. Critical assessment of lifelong phenotype correction in hyperbilirubinemic Gunn rats after retroviral mediated gene transfer. Gene Ther.14(17), 1270–1277 (2007).
   PubMedGoogle Scholar
• van der Wegen P, Louwen R, Imam AM et al. Successful treatment of UGT1A1 deficiency in a rat model of Crigler–Najjar disease by intravenous administration of a liver-specific lentiviral vector. Mol. Ther.13(2), 374–381 (2006).
   PubMed Web of Science ®Google Scholar
• Seppen J, van Til NP, van der Rijt R, Hiralall JK, Kunne C, Elferink RP. Immune response to lentiviral bilirubin UDP-glucuronosyltransferase gene transfer in fetal and neonatal rats. Gene Ther.13(8), 672–677 (2006).
   PubMedGoogle Scholar
• Jia Z, Danko I. Single hepatic venous injection of liver-specific naked plasmid vector expressing human UGT1A1 leads to long-term correction of hyperbilirubinemia and prevention of chronic bilirubin toxicity in Gunn rats. Hum. Gene Ther.16(8), 985–995 (2005).
   PubMedGoogle Scholar
• Danko I, Jia Z, Zhang G. Nonviral gene transfer into liver and muscle for treatment of hyperbilirubinemia in the gunn rat. Hum. Gene Ther.15(12), 1279–1286 (2004).
   PubMedGoogle Scholar
• Tada K, Roy-Chowdhury N, Prasad V et al. Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Cell Transplant.7(6), 607–616 (1998).
   PubMedGoogle Scholar
• Raper SE, Wilson JM. Cell transplantation in liver-directed gene therapy. Cell Transplant.2(5), 381–400 (1993).
   PubMed Web of Science ®Google Scholar
• Seppen J, Tada K, Ottenhoff R et al. Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation. Hum. Gene Ther.8(1), 27–36 (1997).
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Birraux J, Wildhaber B et al.Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. Transplantation82(6), 794–803 (2006).
   PubMed Web of Science ®Google Scholar
• Oertel M, Rosencrantz R, Chen YQ et al. Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. Hepatology37(5), 994–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Kawashita Y, Guha C, Moitra R et al. Hepatic repopulation with stably transduced conditionally immortalized hepatocytes in the Gunn rat. J. Hepatol.49(1), 99–106 (2008).
   PubMedGoogle Scholar
• Strassburg CP. Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics9(6), 703–715 (2008).
   PubMed Web of Science ®Google Scholar
• Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest.101(4), 847–854 (1998).
   PubMed Web of Science ®Google Scholar
• Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol. Pharmacol.43(4), 649–654 (1993).
   PubMed Web of Science ®Google Scholar
• Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res.60(4), 950–956 (2000).
   PubMed Web of Science ®Google Scholar
• Duguay Y, McGrath M, Lepine J et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res.64(3), 1202–1207 (2004).
   PubMed Web of Science ®Google Scholar
• Askari FK, Hitomi Y, Mao M, Wilson JM. Complete correction of hyperbilirubinemia in the Gunn rat model of Crigler–Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP-glucuronosyltransferase. Gene Ther.3(5), 381–388 (1996).
   PubMed Web of Science ®Google Scholar
• Dagher I, Boudechiche L, Branger J et al. Efficient hepatocyte engraftment in a nonhuman primate model after partial portal vein embolization. Transplantation82(8), 1067–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Malhi H, Gorla GR, Irani AN, Annamaneni P, Gupta S. Cell transplantation after oxidative hepatic preconditioning with radiation and ischemia-reperfusion leads to extensive liver repopulation. Proc. Natl Acad. Sci. USA99(20), 13114–13119 (2002).
   PubMed Web of Science ®Google Scholar
• Jansen PL. Diagnosis and management of Crigler–Najjar syndrome. Eur. J. Pediatr.158(Suppl. 2), S89–S94 (1999).
   Google Scholar
• Fox IJ, Chowdhury JR, Kaufman SS et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med.338(20), 1422–1426 (1998).
   PubMed Web of Science ®Google Scholar
• Ambrosino G, Varotto S, Strom SC et al. Isolated hepatocyte transplantation for Crigler–Najjar syndrome type 1. Cell Transplant.14(2–3), 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver diseases. Pediatr. Transplant.12(1), 6–13 (2008).
   PubMedGoogle Scholar
• Li Q, Murphree SS, Willer SS, Bolli R, French BA. Gene therapy with bilirubin-UDP-glucuronosyltransferase in the Gunn rat model of Crigler-Najjar syndrome type 1. Hum. Gene Ther.9(4), 497–505 (1998).
   PubMed Web of Science ®Google Scholar
• Ilan Y, Jona VK, Sengupta K et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology26(4), 949–956 (1997).
   PubMed Web of Science ®Google Scholar
• Ilan Y, Prakash R, Davidson A et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J. Clin. Invest.99(5), 1098–1106 (1997).
   PubMedGoogle Scholar
• Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol.71(11), 1531–1539 (2006).
   PubMed Web of Science ®Google Scholar